Cargando…
Purification of anti-glycoconjugate monoclonal antibodies using newly developed porous zirconia particles
Here, we describe porous zirconia particles (PZPs) optimized for the purification of immunoglobulins. PZPs, with a pore size of approximately 10 nm, were designed to specifically interact with antibodies via surface modification with a phosphate functional group. A simple PZP purification method bas...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873262/ https://www.ncbi.nlm.nih.gov/pubmed/33564002 http://dx.doi.org/10.1038/s41598-021-82457-0 |
_version_ | 1783649349576687616 |
---|---|
author | Okuda, Tetsuya Kato, Katsuya Kitamura, Masahiro Kasahara, Shinjiro |
author_facet | Okuda, Tetsuya Kato, Katsuya Kitamura, Masahiro Kasahara, Shinjiro |
author_sort | Okuda, Tetsuya |
collection | PubMed |
description | Here, we describe porous zirconia particles (PZPs) optimized for the purification of immunoglobulins. PZPs, with a pore size of approximately 10 nm, were designed to specifically interact with antibodies via surface modification with a phosphate functional group. A simple PZP purification method based on precipitation enabled efficient purification of mouse anti-glycosphingolipid globoside/Gb4Cer monoclonal IgM (κ-light chains) from hybridoma culture supernatants. Over 99% of contaminating proteins were removed by the PZP purification process, and approximately 50% of the IgM was recovered in the purified fraction after eluting the PZP-adsorbed antibodies with 100 mM phosphate buffer. Other IgG3 and IgM monoclonal antibodies that react with Gb4Cer or α2,6-sialyl LacNAc-modified glycoproteins could also be purified using PZPs and elution buffer at concentrations of 100–500 mM. All of the purified antibodies retained their antigen reactivity and specificity, indicating that PZP purification does not affect antibody function. As PZP purification is also suitable for purification of IgM consisting of λ-light chains and IgG derived from other mammalian species, it is expected to be applied to the purification of a variety of antibodies, including anti-glycoconjugate IgMs. |
format | Online Article Text |
id | pubmed-7873262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78732622021-02-11 Purification of anti-glycoconjugate monoclonal antibodies using newly developed porous zirconia particles Okuda, Tetsuya Kato, Katsuya Kitamura, Masahiro Kasahara, Shinjiro Sci Rep Article Here, we describe porous zirconia particles (PZPs) optimized for the purification of immunoglobulins. PZPs, with a pore size of approximately 10 nm, were designed to specifically interact with antibodies via surface modification with a phosphate functional group. A simple PZP purification method based on precipitation enabled efficient purification of mouse anti-glycosphingolipid globoside/Gb4Cer monoclonal IgM (κ-light chains) from hybridoma culture supernatants. Over 99% of contaminating proteins were removed by the PZP purification process, and approximately 50% of the IgM was recovered in the purified fraction after eluting the PZP-adsorbed antibodies with 100 mM phosphate buffer. Other IgG3 and IgM monoclonal antibodies that react with Gb4Cer or α2,6-sialyl LacNAc-modified glycoproteins could also be purified using PZPs and elution buffer at concentrations of 100–500 mM. All of the purified antibodies retained their antigen reactivity and specificity, indicating that PZP purification does not affect antibody function. As PZP purification is also suitable for purification of IgM consisting of λ-light chains and IgG derived from other mammalian species, it is expected to be applied to the purification of a variety of antibodies, including anti-glycoconjugate IgMs. Nature Publishing Group UK 2021-02-09 /pmc/articles/PMC7873262/ /pubmed/33564002 http://dx.doi.org/10.1038/s41598-021-82457-0 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Okuda, Tetsuya Kato, Katsuya Kitamura, Masahiro Kasahara, Shinjiro Purification of anti-glycoconjugate monoclonal antibodies using newly developed porous zirconia particles |
title | Purification of anti-glycoconjugate monoclonal antibodies using newly developed porous zirconia particles |
title_full | Purification of anti-glycoconjugate monoclonal antibodies using newly developed porous zirconia particles |
title_fullStr | Purification of anti-glycoconjugate monoclonal antibodies using newly developed porous zirconia particles |
title_full_unstemmed | Purification of anti-glycoconjugate monoclonal antibodies using newly developed porous zirconia particles |
title_short | Purification of anti-glycoconjugate monoclonal antibodies using newly developed porous zirconia particles |
title_sort | purification of anti-glycoconjugate monoclonal antibodies using newly developed porous zirconia particles |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873262/ https://www.ncbi.nlm.nih.gov/pubmed/33564002 http://dx.doi.org/10.1038/s41598-021-82457-0 |
work_keys_str_mv | AT okudatetsuya purificationofantiglycoconjugatemonoclonalantibodiesusingnewlydevelopedporouszirconiaparticles AT katokatsuya purificationofantiglycoconjugatemonoclonalantibodiesusingnewlydevelopedporouszirconiaparticles AT kitamuramasahiro purificationofantiglycoconjugatemonoclonalantibodiesusingnewlydevelopedporouszirconiaparticles AT kasaharashinjiro purificationofantiglycoconjugatemonoclonalantibodiesusingnewlydevelopedporouszirconiaparticles |